B
Bullisch
Bullisch · 25%BMRN
$73.71
Szenariopreis
$55.140
+0.772 (+1.40%)Zum Schluss
Loading chart…
- Hoch
- 55.560
- Eröffnung
- 54.750
- Volumengewichteter Durchschnittskurs
- 55.05
- Volumen
- 1.85M
- Marktkap.
- 15.85B
- Tief
- 54.460
- Umsatz
- 101.61M
- EV/EBITDA, TTM
- 12.60
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene.
KI-Analyse of BioMarin Pharmaceutical Inc. (BMRN)
HaltenCurrently, BioMarin Pharmaceutical Inc (BMRN) is not a strong buy due to its low RSI of 10.442, indicating it is oversold, but it also has a forward P/E of 9.3985, which suggests it may be undervalued. The recent negative performance, with a 20-day change of -16.57%, raises concerns, despite positive news regarding clinical trials that could support future growth.
Analystenbewertungen (24)
+58.41% Aufwärtspotenzial
Kaufen
19 Kaufen
5 Halten
0 Verkaufen
Aktuell: 55.14
Tief
60.00
Durchschnitt
87.35
Hoch
120.00
BMO Capital
Überdurchschnittlich
$97
2026-09-15
BMO Capital
2026-09-15
Kursziel
$97
Überdurchschnittlich
Cantor Fitzgerald
Übergewichten
$86
2026-09-01
Cantor Fitzgerald
2026-09-01
Kursziel
$86
Übergewichten
Piper Sandler
Übergewichten
$90
2026-09-01
Piper Sandler
2026-09-01
Kursziel
$90
Übergewichten
H.C. Wainwright
Neutral
$60
2026-08-31
H.C. Wainwright
2026-08-31
Kursziel
$60
Neutral
Jefferies
Kaufen
$105
2026-08-31
Jefferies
2026-08-31
Kursziel
$105
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von BioMarin Pharmaceutical Inc. (BMRN) beträgt 9.40, verglichen mit dem 5-Jahres-Durchschnitt von 28.18.
Alphio-AI-Kursszenarien für BMRN
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die BMRN halten
Event-Zeitleiste
News
8.510-09PRnewswireBioMarin Unveils New Data on VOXZOGO's Impact on Growth in Children
5.010-05PRnewswireBioMarin Appoints New Chief People Officer
2.010-02CNBCBioMarin Reports Five-Year Data on Pompe Disease Therapy
9.010-02NewsfilterBioMarin's Combination Therapy Shows Five-Year Efficacy in Pompe Disease
9.510-02PRnewswireLong-term Efficacy of POMBILITI + OPFOLDA in Late-Onset Pompe Disease
BMRN FAQ – beantwortet von Alphio AI
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, BioMarin Pharmaceutical Inc (BMRN) is not a strong buy due to its low RSI of 10.442, indicating it is oversold, but it also has a forward P/E of 9.3985, which suggests it may be undervalued. The recent negative performance, with a 20-day change of -16.57%, raises concerns, despite positive news regarding clinical trials that could support future growth.
24 analysts cover BMRN: 19 rate it Buy, 5 Hold and 0 Sell. The average price target is 87.35.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.